라디오테라노스틱스 시장 규모, 점유율, 동향 분석 보고서 : 방사성 동위 원소별, 어프로치별, 용도별, 지역별, 부문별 예측(2026-2033년)

Radiotheranostics Market Summary

The global radiotheranostics market size was estimated at USD 11.79 billion in 2025 and is projected to reach USD 25.56 billion by 2033, growing at a CAGR of 9.5% from 2026 to 2033. The market represents a precision medicine approach that integrates molecular imaging with targeted radionuclide therapy to enhance patient selection, treatment accuracy, and longitudinal outcome monitoring.

By unifying diagnostics and therapy around the same biological target, radiotheranostics reduces clinical uncertainty, supports individualized dosing strategies, and enables more efficient utilization of advanced oncology resources. For instance, in March 2025, according to Actinium Pharmaceuticals, the company announced progress in its radiotheranostic pipeline, underscoring continued development of targeted radiopharmaceutical therapies, reflecting broader industry momentum toward clinically validated, target-driven treatment platforms. Market adoption is supported by expanding clinical evidence, increasing regulatory acceptance of targeted radiopharmaceuticals, and growing uptake across specialized oncology and nuclear medicine centers, while progression is moderated by constraints related to isotope availability, manufacturing scalability, infrastructure readiness, and reimbursement alignment. Strategic priorities across the ecosystem include innovation in targeting ligands, long-term isotope supply partnerships, and service delivery models that ensure consistent and compliant clinical deployment across care settings.

The current radiotheranostics market scenario is characterized by steady clinical expansion and increasing operational sophistication, as the modality moves from early adoption toward more structured integration within oncology care pathways. Development activity is increasingly focused on improving targeting accuracy, optimizing radionuclide selection, and embedding advanced imaging and dosimetry tools to support personalized treatment planning. Innovation is no longer limited to established peptide based radioligands, with growing investment in antibody fragments, engineered peptides, and small molecule vectors that enhance tumor specificity and therapeutic index. Parallel advances in alpha emitter programs are shaping next generation pipelines aimed at addressing resistant and metastatic disease settings.

Despite this momentum, market progression continues to be moderated by practical constraints related to isotope availability, manufacturing scalability, cold chain logistics, and infrastructure readiness across treatment centers. Health systems are evaluating hub and spoke delivery models and external radiopharmacy partnerships to manage complexity while preserving access. Reimbursement alignment remains a critical factor, as payers assess clinical value across both diagnostic and therapeutic components. For instance, in October 2024, according to SHINE Technologies (company press release), collaborative preclinical research demonstrated promising tumor regression outcomes for novel radiotheranostic candidates in prostate and kidney cancer models, underscoring sustained innovation at the intersection of isotope production and targeted radiopharmaceutical development.

Global Radiotheranostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global radiotheranostics market report based on radioisotope, approach, application, and region:

• Radioisotope Outlook (Revenue, USD Million, 2021 - 2033)
• Iodine-131
• Iodine-123
• Gallium-68
• Lutetium-177
• 18F with Y-90
• Others
• Approach Outlook (Revenue, USD Million, 2021 - 2033)
• Targeted Therapeutic
• Targeted Diagnostic
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
  • Thyroid Cancer
  • Neuroendocrine Tumor
  • Hepatocellular Carcinoma
  • Prostate Cancer
  • Others
• Non-Oncology
  • Neurological Disorders
  • Arthritis
  • Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1 Market Segmentation & Scope
• 1.2 Segment Definitions
  • 1.2.1 Radioisotope
  • 1.2.2 Approach
  • 1.2.3 Application
• 1.3 Estimates and Forecast Timeline
• 1.4 Research Methodology
• 1.5 Information Procurement
  • 1.5.1 Purchased Database
  • 1.5.2 GVR's Internal Database
  • 1.5.3 Secondary Sources
  • 1.5.4 Primary Research
• 1.6 Information Analysis
  • 1.6.1 Data Analysis Models
• 1.7 Market Formulation & Data Visualization
• 1.8 Model Details
  • 1.8.1 Commodity Flow Analysis
• 1.9 List of Secondary Sources
• 1.10 Objectives

Chapter 2. Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot
• 2.3 Competitive Landscape Snapshot

Chapter 3 Radiotheranostics Market Variables, Trends, & Scope

• 3.1 Market Lineage Outlook
• 3.2 Market Dynamics
  • 3.2.1 Market Driver Analysis
  • 3.2.2 Market Restraint Analysis
• 3.3 Business Environment Analysis
  • 3.3.1 Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1 Supplier Power
    • 3.3.1.2 Buyer Power
    • 3.3.1.3 Substitution Threat
    • 3.3.1.4 Threat of New Entrants
    • 3.3.1.5 Competitive Rivalry
  • 3.3.2 PESTLE Analysis
  • 3.3.3 Pipeline Analysis
  • 3.3.4 Patent Expiry Analysis
  • 3.3.5 Pricing Analysis

Chapter 4. Radiotheranostics Market: Radioisotope Business Analysis

• 4.1. Radioisotope Market Share, 2025 & 2033
• 4.2. Radioisotope Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Radioisotope, 2021 to 2033 (USD Million)
• 4.4. Iodine-131
  • 4.4.1 Iodine-131 Market, 2021 - 2033 (USD Million)
• 4.5. Iodine-123
  • 4.5.1 Iodine-123 Market, 2021 - 2033 (USD Million)
• 4.6. Gallium-68
  • 4.6.1 Gallium-68 Market, 2021 - 2033 (USD Million)
• 4.7. Lutetium-177
  • 4.7.1 Lutetium-177 Market, 2021 - 2033 (USD Million)
• 4.8. 18F with Y-90
  • 4.8.1 18F with Y-90 Market, 2021 - 2033 (USD Million)
• 4.9. Others
  • 4.9.1 Others Market, 2021 - 2033 (USD Million)

Chapter 5. Radiotheranostics Market: Approach Business Analysis

• 5.1. Approach Market Share, 2025 & 2033
• 5.2. Approach Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Approach, 2021 to 2033 (USD Million)
• 5.4. Targeted Therapeutic
  • 5.4.1 Targeted Therapeutic Market, 2021 - 2033 (USD Million)
• 5.5. Targeted Diagnostic
  • 5.5.1 Targeted Diagnostic Market, 2021 - 2033 (USD Million)

Chapter 6. Radiotheranostics Market: Application Business Analysis

• 6.1. Application Market Share, 2025 & 2033
• 6.2. Application Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Oncology
  • 6.4.1 Oncology Market, 2021 - 2033 (USD Million)
    • 6.4.1.1 Thyroid Cancer Market, 2021 - 2033 (USD Million)
    • 6.4.1.2 Neuroendocrine Tumor Market, 2021 - 2033 (USD Million)
    • 6.4.1.3 Hepatocellular Carcinoma Market, 2021 - 2033 (USD Million)
    • 6.4.1.4 Prostate Cancer Market, 2021 - 2033 (USD Million)
    • 6.4.1.5 Others Market, 2021 - 2033 (USD Million)
• 6.5. Non-Oncology
  • 6.5.1 Non-Oncology Market, 2021 - 2033 (USD Million)
    • 6.5.1.1 Neurological Disorders Market, 2021 - 2033 (USD Million)
    • 6.5.1.2 Arthritis Market, 2021 - 2033 (USD Million)
    • 6.5.1.3 Others Market, 2021 - 2033 (USD Million)

Chapter 7. Radiotheranostics Market: Regional Estimates & Trend Analysis

• 7.1 Regional Market Share Analysis, 2025 & 2033
• 7.2 Regional Market Dashboard
• 7.3 Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 7.4 North America
  • 7.4.1 North America Radiotheranostics Market Estimates and Forecasts, By Country, 2021-2033 (USD Million)
  • 7.4.2 U.S.
    • 7.4.2.1 Key Country Dynamics
    • 7.4.2.2 Regulatory Framework
    • 7.4.2.3 Reimbursement Scenario
    • 7.4.2.4 U.S. Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.4.3 Canada
    • 7.4.3.1 Key Country Dynamics
    • 7.4.3.2 Regulatory Framework
    • 7.4.3.3 Reimbursement Scenario
    • 7.4.3.4 Canada Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.4.4 Mexico
    • 7.4.4.1 Key Country Dynamics
    • 7.4.4.2 Regulatory Framework
    • 7.4.4.3 Reimbursement Scenario
    • 7.4.4.4 Mexico Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
• 7.5 Europe
  • 7.5.1 Europe Radiotheranostics Market Estimates and Forecasts, By Country, 2021-2033 (USD Million)
  • 7.5.2 UK
    • 7.5.2.1 Key Country Dynamics
    • 7.5.2.2 Regulatory Framework
    • 7.5.2.3 Reimbursement Scenario
    • 7.5.2.4 UK Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.5.3 Germany
    • 7.5.3.1 Key Country Dynamics
    • 7.5.3.2 Regulatory Framework
    • 7.5.3.3 Reimbursement Scenario
    • 7.5.3.4 Germany Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.5.4 France
    • 7.5.4.1 Key Country Dynamics
    • 7.5.4.2 Regulatory Framework
    • 7.5.4.3 Reimbursement Scenario
    • 7.5.4.4 France Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.5.5 Italy
    • 7.5.5.1 Key Country Dynamics
    • 7.5.5.2 Regulatory Framework
    • 7.5.5.3 Reimbursement Scenario
    • 7.5.5.4 Italy Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.5.6 Spain
    • 7.5.6.1 Key Country Dynamics
    • 7.5.6.2 Regulatory Framework
    • 7.5.6.3 Reimbursement Scenario
    • 7.5.6.4 Spain Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.5.7 Denmark
    • 7.5.7.1 Key Country Dynamics
    • 7.5.7.2 Regulatory Framework
    • 7.5.7.3 Reimbursement Scenario
    • 7.5.7.4 Denmark Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.5.8 Norway
    • 7.5.8.1 Key Country Dynamics
    • 7.5.8.2 Regulatory Framework
    • 7.5.8.3 Reimbursement Scenario
    • 7.5.8.4 Norway Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.5.9 Sweden
    • 7.5.7.1 Key Country Dynamics
    • 7.5.7.2 Regulatory Framework
    • 7.5.7.3 Reimbursement Scenario
    • 7.5.7.4 Sweden Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
• 7.6 Asia Pacific
  • 7.6.1 Asia Pacific Radiotheranostics Market Estimates and Forecasts, By Country, 2021-2033 (USD Million)
  • 7.6.2 Japan
    • 7.6.2.1 Key Country Dynamics
    • 7.6.2.2 Regulatory Framework
    • 7.6.2.3 Reimbursement Scenario
    • 7.6.2.4 Japan Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.6.3 China
    • 7.6.3.1 Key Country Dynamics
    • 7.6.3.2 Regulatory Framework
    • 7.6.3.3 Reimbursement Scenario
    • 7.6.3.4 China Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.6.4 India
    • 7.6.4.1 Key Country Dynamics
    • 7.6.4.2 Regulatory Framework
    • 7.6.4.3 Reimbursement Scenario
    • 7.6.4.4 India Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.6.5 South Korea
    • 7.6.5.1 Key Country Dynamics
    • 7.6.5.2 Regulatory Framework
    • 7.6.5.3 Reimbursement Scenario
    • 7.6.5.4 South Korea Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.6.6 Australia
    • 7.6.6.1 Key Country Dynamics
    • 7.6.6.2 Regulatory Framework
    • 7.6.6.3 Reimbursement Scenario
    • 7.6.6.4 Australia Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.6.7 Thailand
    • 7.6.7.1 Key Country Dynamics
    • 7.6.7.2 Regulatory Framework
    • 7.6.7.3 Reimbursement Scenario
    • 7.6.7.4 Thailand Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
• 7.7 Latin America
  • 7.7.1 Latin America Radiotheranostics Market Estimates and Forecasts, By Country, 2021-2033 (USD Million)
  • 7.7.2 Brazil
    • 7.7.2.1 Key Country Dynamics
    • 7.7.2.2 Regulatory Framework
    • 7.7.2.3 Reimbursement Scenario
    • 7.7.2.4 Brazil Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.7.3 Argentina
    • 7.7.3.1 Key Country Dynamics
    • 7.7.3.2 Regulatory Framework
    • 7.7.3.3 Reimbursement Scenario
    • 7.7.3.4 Argentina Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
• 7.8 Middle East & Africa
  • 7.8.1 Middle East & Africa Radiotheranostics Market Estimates and Forecasts, By Country, 2021-2033 (USD Million)
  • 7.8.2 South Africa
    • 7.8.2.1 Key Country Dynamics
    • 7.8.2.2 Regulatory Framework
    • 7.8.2.3 Reimbursement Scenario
    • 7.8.2.4 South Africa Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.8.3 Saudi Arabia
    • 7.8.3.1 Key Country Dynamics
    • 7.8.3.2 Regulatory Framework
    • 7.8.3.3 Reimbursement Scenario
    • 7.8.3.4 Saudi Arabia Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.8.4 UAE
    • 7.8.4.1 Key Country Dynamics
    • 7.8.4.2 Regulatory Framework
    • 7.8.4.3 Reimbursement Scenario
    • 7.8.4.4 UAE Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 7.8.5 Kuwait
    • 7.8.5.1 Key Country Dynamics
    • 7.8.5.2 Regulatory Framework
    • 7.8.5.3 Reimbursement Scenario
    • 7.8.5.4 Kuwait Radiotheranostics Market Estimates and Forecasts, 2021-2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1 Bayer
    • 8.5.1.1 Overview
    • 8.5.1.2 Financial Performance
    • 8.5.1.3 Product Benchmarking
    • 8.5.1.4 Strategic Initiatives
  • 8.5.2 Lantheus Holdings
    • 8.5.2.1 Overview
    • 8.5.2.2 Financial Performance
    • 8.5.2.3 Product Benchmarking
    • 8.5.2.4 Strategic Initiatives
  • 8.5.3 POINT Biopharma
    • 8.5.3.1 Overview
    • 8.5.3.2 Financial Performance
    • 8.5.3.3 Product Benchmarking
    • 8.5.3.4 Strategic Initiatives
  • 8.5.4 Telix Pharmaceuticals
    • 8.5.4.1 Overview
    • 8.5.4.2 Financial Performance
    • 8.5.4.3 Product Benchmarking
    • 8.5.4.4 Strategic Initiatives
  • 8.5.5 Actinium Pharmaceuticals
    • 8.5.5.1 Overview
    • 8.5.5.2 Financial Performance
    • 8.5.5.3 Product Benchmarking
    • 8.5.5.4 Strategic Initiatives
  • 8.5.6 RadioMedix
    • 8.5.6.1 Overview
    • 8.5.6.2 Financial Performance
    • 8.5.6.3 Product Benchmarking
    • 8.5.6.4 Strategic Initiatives
  • 8.5.7 IsoRay
    • 8.5.7.1 Overview
    • 8.5.7.2 Financial Performance
    • 8.5.7.3 Product Benchmarking
    • 8.5.7.4 Strategic Initiatives
  • 8.5.8 SHINE Technologies
    • 8.5.8.1 Overview
    • 8.5.8.2 Financial Performance
    • 8.5.8.3 Product Benchmarking
    • 8.5.8.4 Strategic Initiatives
  • 8.5.9 NorthStar Medical Radioisotopes
    • 8.5.9.1 Overview
    • 8.5.9.2 Financial Performance
    • 8.5.9.3 Product Benchmarking
    • 8.5.9.4 Strategic Initiatives
  • 8.5.10 Fusion Pharmaceuticals
    • 8.5.10.1 Overview
    • 8.5.10.2 Financial Performance
    • 8.5.10.3 Product Benchmarking
    • 8.5.10.4 Strategic Initiatives
  • 8.5.11 Novartis
    • 8.5.11.1 Overview
    • 8.5.11.2 Financial Performance
    • 8.5.11.3 Product Benchmarking
    • 8.5.11.4 Strategic Initiatives